Value for money of medicine sampling and quality testing: evidence from Indonesia
Our findings bring urgently needed and novel information on the cost and value for money of medicine quality surveillance. These may support planning and budgeting of the Indonesian pharmaceutical regulator, but also of regulators and researchers elsewhere, particularly in low-income and middle-income settings, as well as international organisations with health regulation and quality of care remits.
Authors
- Amalia Hasnida (ORCID: https://orcid.org/0000-0002-9264-334X)
- Yusi Anggriani (ORCID: https://orcid.org/0000-0001-7787-0539)
- Katharina Hauck (ORCID: https://orcid.org/0000-0003-3138-4169)
- Sara Valente de Almeida (ORCID: https://orcid.org/0000-0001-9178-2105)
- Stanley Saputra (ORCID: https://orcid.org/0009-0006-5969-0183)
- Elizabeth Pisani (ORCID: https://orcid.org/0000-0002-3674-631X)
- Adrian Gheorghe (ORCID: https://orcid.org/0000-0002-0517-8807)
- Ayu Rahmawati (ORCID: https://orcid.org/0009-0001-2757-6670)
- Sarah Njenga
- Yunita Nugrahani
- Rahmi Mawaddati
Institutions
- King's College London (GB)
- Pancasila University (ID)
- Public Health England (GB)
- University of Oxford (GB)
- Imperial College London (GB)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- BMJ Global Health
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1136/bmjgh-2024-015402
- Citations
- 5
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 5.65
Funders
- National Institute for Health and Care Research
- Imperial College London
- Erasmus Universiteit Rotterdam
- Medical Research Council